Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer

[1]  Jordi Giralt,et al.  Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Likun Chen,et al.  Osteopontin is a useful predictor of bone metastasis and survival in patients with locally advanced nasopharyngeal carcinoma , 2015, International journal of cancer.

[3]  Miao-Fen Chen,et al.  TGF Beta1 Expression Correlates with Survival and Tumor Aggressiveness of Prostate Cancer , 2015, Annals of Surgical Oncology.

[4]  G. Garlet,et al.  Intramembranous Bone Healing Process Subsequent to Tooth Extraction in Mice: Micro-Computed Tomography, Histomorphometric and Molecular Characterization , 2015, PloS one.

[5]  Ulrich Keilholz,et al.  Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. , 2015, The Lancet. Oncology.

[6]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[7]  K. Ang,et al.  Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Jiwang Zhang,et al.  Osteopontin Mediates an MZF1-TGF-β1-Dependent Transformation of Mesenchymal Stem Cells into Cancer Associated Fibroblasts in Breast Cancer , 2014, Oncogene.

[9]  Sue S Yom,et al.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Tas,et al.  High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer , 2014, Tumor Biology.

[11]  F. Tas,et al.  Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer , 2014, Tumor Biology.

[12]  G. Kalna,et al.  Identification of two distinct carcinoma-associated fibroblast subtypes with differential tumor-promoting abilities in oral squamous cell carcinoma. , 2013, Cancer research.

[13]  B. Kong,et al.  Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1 , 2013, Cellular and Molecular Immunology.

[14]  T. Yen,et al.  Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer , 2012, Clinical chemistry and laboratory medicine.

[15]  Lei Du,et al.  Reciprocal Interactions between Tumor-Associated Macrophages and CD44-Positive Cancer Cells via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer , 2012, Clinical Cancer Research.

[16]  P. Kuo,et al.  Epithelial-Mesenchymal Transition, TGF-&bgr;, and Osteopontin in Wound Healing and Tissue Remodeling After Injury , 2012, Journal of burn care & research : official publication of the American Burn Association.

[17]  N. Tan,et al.  Matricellular Proteins: A Sticky Affair with Cancers , 2012, Journal of oncology.

[18]  V. Grégoire,et al.  Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. , 2012, The Lancet. Oncology.

[19]  M. Flentje,et al.  Influence of osteopontin silencing on survival and migration of lung cancer cells , 2012, Strahlentherapie und Onkologie.

[20]  R. Fisher,et al.  Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial , 2011, Clinical Cancer Research.

[21]  K. Okuno,et al.  Osteopontin Induced by Macrophages Contribute to Metachronous Liver Metastases in Colorectal Cancer , 2011, The American surgeon.

[22]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  A. Weiss,et al.  Serum transforming growth factor beta-1 post hip fracture repair in elderly patients. , 2011, Cytokine.

[24]  M. Flentje,et al.  Osteopontin Plasma Levels in Head and Neck Cancer Patients During Radiotherapy , 2010 .

[25]  Kohei Miyazono,et al.  TGFβ signalling: a complex web in cancer progression , 2010, Nature Reviews Cancer.

[26]  H. Pass,et al.  Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  J. Crowley,et al.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Matthew Sydes,et al.  Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. , 2008, The Lancet. Oncology.

[30]  V. Castronovo,et al.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer , 2008, Nature Reviews Cancer.

[31]  M. Nosrati,et al.  Osteopontin as a molecular prognostic marker for melanoma , 2008, Cancer.

[32]  H. Taubert,et al.  Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. , 2006, International journal of radiation oncology, biology, physics.

[33]  M. Kaplan,et al.  Plasma osteopontin is an independent prognostic marker for head and neck cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Bache,et al.  Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system , 2006, BMC Cancer.

[35]  V. Bramwell,et al.  Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[36]  Robert Tibshirani,et al.  An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non–Small Cell Lung Cancers , 2006, Clinical Cancer Research.

[37]  J. Overgaard,et al.  Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. , 2005, The Lancet. Oncology.

[38]  E. Rosenthal,et al.  Elevated expression of TGF‐β1 in head and neck cancer–associated fibroblasts , 2004, Molecular carcinogenesis.

[39]  A. Barbul,et al.  Understanding the role of immune regulation in wound healing. , 2004, American journal of surgery.

[40]  M. Kattan,et al.  Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor β1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression , 2004, Clinical Cancer Research.

[41]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.